OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Neuropathic Corneal Pain
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic Conjunctivitis 
    • NCP Expanded Access
  • Technology
    • Chemerin Receptor
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
    • FAQs
  • News
    • Press releases
    • Media
  • Contact
  • Linkedin
  • Twitter
Select Page
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

by Paul | 30th October 2024 | News

London and New York, NY, October 30, 2024. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy,...

Recent Posts

  • OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
  • OKYO Pharma Announces Chairman and Founder Acquires Shares
  • OKYO Pharma Announces Chairman and Founder Acquires Shares
  • OKYO Pharma to Present at OIS XV in San Diego
  • OKYO Pharma to Present at BIO-Europe 2025 in Vienna

Recent Comments

No comments to show.
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Technology
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023